Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWUU | ISIN: US00534A1025 | Ticker-Symbol:
NASDAQ
27.06.25 | 21:58
0,744 US-Dollar
-6,83 % -0,055
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INVIVYD INC Chart 1 Jahr
5-Tage-Chart
INVIVYD INC 5-Tage-Chart

Aktuelle News zur INVIVYD Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrH.C. Wainwright behält Kaufempfehlung für Invivyd-Aktie nach positiven Daten bei2
FrH.C. Wainwright maintains buy rating on Invivyd stock after positive data1
DoInvivyd claims Pemgarda mAB follow-up could hold its own against COVID vaccines1
INVIVYD Aktie jetzt für 0€ handeln
DoInvivyd, Inc. - 8-K, Current Report1
DoInvivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection59Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate...
► Artikel lesen
29.05.H.C. Wainwright senkt Kursziel für Invivyd-Aktie auf 5 US-Dollar, behält Kaufempfehlung bei-
29.05.Invivyd stock target cut to $5 by H.C. Wainwright, retains Buy rating2
27.05.Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, ...201CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal...
► Artikel lesen
23.05.Invivyd's antibody gains spot in cancer guidelines for COVID-19 PrEP2
23.05.Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas145WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National...
► Artikel lesen
21.05.Invivyd Says Pemivibart Confers 84% Reduction In COVID-19 Risk, To Engage FDA With Expedited Pathway1
21.05.Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19154FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by the Agency generally...
► Artikel lesen
20.05.Invivyd, Inc. - 8-K, Current Report4
15.05.Invivyd Q1 2025 slides: Revenue grows amid regulatory hurdles and cash concerns3
15.05.Invivyd GAAP EPS of -$0.14 misses by $0.11, revenue of $11.3M misses by $23.15M3
15.05.Invivyd, Inc. - 10-Q, Quarterly Report1
15.05.Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights119PEMGARDA (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales forcePEMGARDA revenue re-acceleration...
► Artikel lesen
14.05.What to Expect from Invivyd's Earnings1
14.05.Invivyd fordert modernisierte FDA-Impfstoffrichtlinien2
14.05.Invivyd calls for modernized FDA vaccine guidelines1
Weiter >>
73 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1